score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		PROS10448-1115153	PROS10448-1115153-Tumor-SM-5EEBL	
Investigate Actionability - High		Clinical evidence		Somatic Variant	AR	Missense	p.Q58L	0.0127	628.0	0.0	0.0								Investigate Actionability - High	Abiraterone	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	0.0	0.0	0.0	AR p.Q58L (Missense)		PROS10448-1115153	PROS10448-1115153-Tumor-SM-5EEBL	PROS10448-1115153-Normal-SM-4YS2H
Biologically Relevant				Copy Number	RBM10	Amplification				0.0	0.0																			0				RBM10 Amplification		PROS10448-1115153	PROS10448-1115153-Tumor-SM-5EEBL	
Biologically Relevant				Copy Number	TSC2	Amplification				0.0	0.0																			0				TSC2 Amplification		PROS10448-1115153	PROS10448-1115153-Tumor-SM-5EEBL	
Biologically Relevant				Copy Number	BCOR	Amplification				0.0	0.0																			0				BCOR Amplification		PROS10448-1115153	PROS10448-1115153-Tumor-SM-5EEBL	
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH3 p.63_64insAAP (Insertion)																							0				Supporting variants: MSH3 p.63_64insAAP (Insertion)		PROS10448-1115153		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.517																							0				COSMIC Signature 1 (52%)		PROS10448-1115153		
Biologically Relevant				Mutational Signature	COSMIC Signature 15		0.2																							0				COSMIC Signature 15 (20%)		PROS10448-1115153		
